Form 8-K - Current report:
SEC Accession No. 0001140361-23-044154
Filing Date
2023-09-15
Accepted
2023-09-15 16:30:19
Documents
12
Period of Report
2023-09-12
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20010786_8k.htm   iXBRL 8-K 39111
  Complete submission text file 0001140361-23-044154.txt   180551

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA roiv-20230912.xsd EX-101.SCH 3862
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE roiv-20230912_lab.xml EX-101.LAB 23290
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE roiv-20230912_pre.xml EX-101.PRE 16550
6 EXTRACTED XBRL INSTANCE DOCUMENT ef20010786_8k_htm.xml XML 4365
Mailing Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Business Address CLARENDON HOUSE, 2 CHURCH STREET HAMILTON HM11 D0 HM11 441-295-5950
Roivant Sciences Ltd. (Filer) CIK: 0001635088 (see all company filings)

EIN.: 981173944 | State of Incorp.: D0 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-40782 | Film No.: 231259151
SIC: 2834 Pharmaceutical Preparations